Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: results from HORIZON-PFT

被引：0
|
作者：
Miller, P.
Sellmeyer, D.
Boonen, S.
机构：
来源：
OSTEOPOROSIS INTERNATIONAL | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S129 / S130
页数：2
相关论文
共 50 条
  • [21] Effect of zoledronic acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: Results from horizon-PFT
    Cauley, J. A.
    Adachi, J.
    Cosman, F.
    Black, D.
    Boonen, S. R.
    Cummings, S.
    Delmas, P.
    Eastell, R.
    BONE, 2007, 40 (06) : S132 - S132
  • [22] Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: The HORIZON Pivotal Fracture Trial.
    Black, D. M.
    Boonen, S.
    Cauley, J.
    Delmas, P.
    Eastell, R.
    Reid, I.
    Rosario-Jansen, T.
    Caminis, J.
    Zhang, J.
    Hu, H.
    Cummings, S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S16 - S16
  • [23] Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: The HORIZON pivotal fracture trial.
    Black, D. M.
    Boonen, S.
    Cauley, J.
    Delmas, P.
    Eastell, R.
    Reid, I.
    Rosario-Jansen, T.
    Caminis, J.
    Zhang, J.
    Hu, H.
    Cummings, S.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S305 - S305
  • [24] Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis
    Woodis, C. Brock
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (7-8) : 1085 - 1089
  • [25] Relationship of Bone Turnover Marker (PINP) and Changes in Femoral Neck Bone Mineral Density to Fracture Risk in Women with Postmenopausal Osteoporosis Treated with Once-Yearly Zoledronic Acid 5 mg (ZOL.): The HORIZON-PFT Study
    Delmas, P. D.
    Munoz, F.
    Cosman, F.
    Boonen, S.
    Black, D.
    Watts, N. B.
    Kendler, D.
    Eriksen, E. F.
    Mesenbrink, P.
    Eastell, R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S9 - S9
  • [26] Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older
    Boonen, Steven
    Black, Dennis M.
    Colon-Emeric, Cathleen S.
    Eastell, Richard
    Magaziner, Jay S.
    Eriksen, Erik Fink
    Mesenbrink, Peter
    Haentjens, Patrick
    Lyles, Kenneth W.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 (02) : 292 - 299
  • [27] EFFECT OFA ONCE-YEARLY ZOLEDRONIC ACID ON BMD AND THE RISK OF FALLING IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Lin, H.
    Xu, T.
    Fan, L.
    Yang, H.
    Chen, X.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S649 - S650
  • [28] Increased integral bone mineral density (BMD) of the hip with once-yearly zoledronic acid 5 mg (ZOL): Quantitative computed tomography data (QCT) from the horizon-pft trial
    Eastell, R.
    Lang, T.
    Boonen, S.
    Cummings, S.
    Delmas, P. D.
    Cauley, J.
    Horowitz, Z.
    Kerzberg, E.
    Leung, P.
    Man, Z.
    Mesenbrink, P.
    Eriksen, E. F.
    Black, D.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S54 - S55
  • [29] RENAL EFFECTS OF TREATMENT WITH ZOLEDRONIC ACID: RESULTS FROM THE HORIZON-PFT EXTENSION STUDY
    Miller, Paul D.
    Black, Dennis M.
    Hruska, Josef
    Boonen, Steven
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S197 - S198
  • [30] HORIZON: Yearly infusion of zoledronic acid reduces risk of fracture in postmenopausal women with osteoporosis
    不详
    FORMULARY, 2007, 42 (08) : 488 - 489
12345